Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could 3 days beat 14? new study tests shorter catheter use for sudden urinary blockage

NCT ID NCT07283484

Symptom relief Sponsor: Liselot Ribbert Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Acute urinary retention (AUR) is a sudden inability to urinate, often due to an enlarged prostate. The RELIEF study compares removing the catheter after 3 days versus the usual 14 days in 478 men. All participants receive a catheter and prostate medication. The goal is to see if a shorter duration is equally successful at restoring normal urination, while reducing discomfort and complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
alpha-blocker medication (tamsulosin, silodosin, or alfuzosin)
What this could lead to
If successful, this could lead to shorter, more comfortable catheter use for men with acute urinary retention, reducing infections and improving quality of life.
What could go wrong
This is a mid-sized trial, and results may not apply to all patients. A shorter catheter duration might increase the risk of needing re-catheterization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 478 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult men (≥18 years) * Diagnosis of acute urinary retention (AUR) treated with a transurethral catheter (TUC) and alpha-blocker therapy (tamsulosin, silodosin, or alfuzosin) * Mentally competent and able to understand the potential benefits and burdens of study participation * Provision of written or digital informed consent Exclusion Criteria: * Failed prior TWOC within the preceding 30 days * Initial urinary retention volume \>1500 mL * Neurogenic bladder dysfunction (e.g., multiple sclerosis, spinal cord injury, spina bifida) * History of prostate cancer with ISUP grade group ≥2 * History of active bladder cancer or ongoing surveillance for bladder cancer * Urinary retention occurring within 72 hours after surgery (postoperative urinary retention) * History of lower urinary tract surgery (e.g., bladder augmentation, urethral surgery, or prostate surgery) * AUR suspected to be caused by bladder stones * Suspected urethral stricture, clot retention, or urosepsis * Contraindication to alpha-blocker therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute urinary retention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia Urinary Retention

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute urinary retention Benign prostate hyperplasia Benign prostate hypertrophy(BPH) Benign prostate obstruction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alrijne Hospital

    RECRUITING

    Leiderdorp, South Holland, 2353 GA, Netherlands

  • Canisius Wilhelmina Hospital

    RECRUITING

    Nijmegen, Gelderland, 6532SZ, Netherlands

  • Catharina Hospital

    RECRUITING

    Eindhoven, North Brabant, 5623 EJ, Netherlands

  • Isala

    RECRUITING

    Zwolle, Overijssel, 8025AB, Netherlands

  • Maastricht University Medical Center+

    RECRUITING

    Maastricht, Limburg, 6229 HX, Netherlands

  • Martini Hospital

    RECRUITING

    Groningen, Provincie Groningen, 9728NT, Netherlands

  • OLVG

    RECRUITING

    Amsterdam, North Holland, 1091 AC, Netherlands

  • Spaarne Gasthuis

    NOT_YET_RECRUITING

    Hoofddorp, North Holland, 2134 TM, Netherlands

  • St. Jansdal

    NOT_YET_RECRUITING

    Harderwijk, Gelderland, 3844 DG, Netherlands

  • Ziekenhuisgroep Twente

    NOT_YET_RECRUITING

    Hengelo, Overijssel, 7555 DL, Netherlands

  • Zuyderland Ziekenhuis

    NOT_YET_RECRUITING

    Heerlen, Limburg, 6419 PC, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.